Reclassifying cannabis? Implications for recreational/medical marijuana use, research, drug policy

Quick Overview

President Trump signed an executive order to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, a move that experts agree is extremely close to finalization despite procedural holdups, with the immediate guaranteed benefit being the elimination of the restrictive tax code Section 280E for state-licensed cannabis businesses.

Key Points: The federal rescheduling process was accelerated by President Trump's executive order, building on a 2022 rescheduling petition initiated by President Biden, moving cannabis from Schedule I to Schedule III. Vanderbilt Law Professor Rob Mikos states that the only guaranteed benefit of rescheduling to Schedule III is the elimination of Section 280E, which currently prevents cannabis companies from claiming ordinary tax deductions. Dr. Peter Ginspoon, a primary care doctor, argues that rescheduling constitutes less stigma, better research, and is an admission by the US government that cannabis is a medicine, noting that tobacco kills 500,000 people annually while cannabis is scheduled higher. Ephetio Taio Harvey of the People of Color Psychedelic Collective asserts that rescheduling to Schedule III is "a dollar short and a day late" and does not address the racialized harms of cannabis prohibition, advocating instead for full federal decriminalization or descheduling. Hersh Jane, an industry advisor, notes that rescheduling will catalyze long-term changes in banking access, state-level reform, federal policy, and the international landscape, even if these changes are not immediate. Rob Mikos clarifies that rescheduling does not automatically legalize sales, as Schedule III drugs still require DEA licensing, and selling marijuana still violates the Food Drug and Cosmetic Act because HHS emphatically stated it is not approving marijuana as a drug. Dr. Ginspoon hopes rescheduling will decrease stigma, lower prices by eliminating 280E costs, and improve research by allowing scientists to study the actual cannabis products patients use, rather than only government-supplied samples.